Literature DB >> 31445112

Innovations in efforts to expand treatment for opioid use disorder.

Stacey C Sigmon1.   

Abstract

Fewer than 20% of Americans with opioid use disorder receive empirically-supported treatment. There is a critical need for innovative approaches to support expansion of evidence-based opioid treatment, particularly in rural geographic areas so impacted by the current opioid public health crisis. Doing so will require more diverse pathways into treatment, novel pharmacological tools, improved integration and efficiency among treatment modalities, and harm reduction when treatment is not available. In this invited commentary, we review exciting recent efforts to accomplish these aims as well as offer additional considerations for future clinical and research efforts to increase the availability of treatment for opioid use disorder.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Agonist maintenance; Buprenorphine; Methadone; Opioid use disorder; Treatment

Mesh:

Substances:

Year:  2019        PMID: 31445112      PMCID: PMC7081076          DOI: 10.1016/j.ypmed.2019.105818

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  21 in total

1.  Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder.

Authors:  Azmi F Nasser; Mark K Greenwald; Bradley Vince; Paul J Fudala; Philip Twumasi-Ankrah; Yongzhen Liu; J P Jones; Christian Heidbreder
Journal:  J Clin Psychopharmacol       Date:  2016-02       Impact factor: 3.153

2.  Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial.

Authors:  Richard N Rosenthal; Michelle R Lofwall; Sonnie Kim; Michael Chen; Katherine L Beebe; Frank J Vocci
Journal:  JAMA       Date:  2016-07-19       Impact factor: 56.272

3.  Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial.

Authors:  Michelle R Lofwall; Sharon L Walsh; Edward V Nunes; Genie L Bailey; Stacey C Sigmon; Kyle M Kampman; Michael Frost; Fredrik Tiberg; Margareta Linden; Behshad Sheldon; Sonia Oosman; Stefan Peterson; Michael Chen; Sonnie Kim
Journal:  JAMA Intern Med       Date:  2018-06-01       Impact factor: 21.873

4.  Expanding access to buprenorphine treatment in rural areas with the use of telemedicine.

Authors:  Eric Weintraub; Aaron David Greenblatt; Joy Chang; Seth Himelhoch; Christopher Welsh
Journal:  Am J Addict       Date:  2018-09-28

5.  Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential.

Authors:  Stacey C Sigmon; George E Bigelow
Journal:  Addiction       Date:  2016-08-26       Impact factor: 6.526

6.  Putting Parity into Practice - Integrating Opioid-Use Disorder Treatment into the Hospital Setting.

Authors:  Laura Fanucchi; Michelle R Lofwall
Journal:  N Engl J Med       Date:  2016-09-01       Impact factor: 91.245

Review 7.  The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review.

Authors:  Linda Vona-Davis; David P Rose
Journal:  J Womens Health (Larchmt)       Date:  2009-06       Impact factor: 2.681

8.  A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry.

Authors:  Michael S Gordon; Timothy W Kinlock; Robert P Schwartz; Terrence T Fitzgerald; Kevin E O'Grady; Frank J Vocci
Journal:  Drug Alcohol Depend       Date:  2014-06-02       Impact factor: 4.492

9.  Opiate-dependent patients on a waiting list for methadone maintenance treatment are at high risk for mortality until treatment entry.

Authors:  Einat Peles; Shaul Schreiber; Miriam Adelson
Journal:  J Addict Med       Date:  2013 May-Jun       Impact factor: 3.702

10.  Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program.

Authors:  Marcus A Bachhuber; Cole Thompson; Ann Prybylowski; José Benitez; Silvana Mazzella; David Barclay
Journal:  Subst Abus       Date:  2018-05-04       Impact factor: 3.984

View more
  4 in total

1.  The next wave? Mental health comorbidities and patients with substance use disorders in under-resourced and rural areas.

Authors:  Sara C Warfield; Robert P Pack; Louisa Degenhardt; Sarah Larney; Chrianna Bharat; Lisham Ashrafioun; Brandon D L Marshall; Robert M Bossarte
Journal:  J Subst Abuse Treat       Date:  2020-11-04

2.  Opioid Treatment Deserts: Concept development and application in a US Midwestern urban county.

Authors:  Ayaz Hyder; Jinhyung Lee; Ashley Dundon; Lauren T Southerland; David All; Gretchen Hammond; Harvey J Miller
Journal:  PLoS One       Date:  2021-05-12       Impact factor: 3.240

Review 3.  Implications of Increased Access to Buprenorphine for Medical Providers in Rural Areas: A Review of the Literature and Future Directions.

Authors:  Hannah M Gregory; Veronica M Hill; Robert W Parker
Journal:  Cureus       Date:  2021-11-24

4.  Comparison of Rural vs Urban Direct-to-Physician Commercial Promotion of Medications for Treating Opioid Use Disorder.

Authors:  Thuy Nguyen; Barbara Andraka-Christou; Kosali Simon; W David Bradford
Journal:  JAMA Netw Open       Date:  2019-12-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.